Collaborative Arrangements - Narrative (Details) - USD ($) $ in Millions	1 Months Ended		12 Months Ended
	Nov. 30, 2021	Mar. 31, 2021	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Amortization			$ 2,085	$ 1,636	$ 1,817
Other intangibles, net			20,269	22,933
Sales			59,283	48,704	41,518
Operating Segments
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Sales			57,555	48,322	41,336
Operating Segments | Pharmaceutical segment
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Sales			52,005	42,754	36,610
License
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Other intangibles, net			3,554	3,368
Lynparza
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Amortization			250		106
Lynparza | License
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Other intangibles, net			1,600
Lenvima | Operating Segments | Pharmaceutical segment
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Sales			876	704	580
Lenvima | License
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Other intangibles, net			814
Adempas | Operating Segments | Pharmaceutical segment
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Sales			238	252	220
Adempas | Licenses and other
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Intangible assets			633
Verquvo | Licenses and other
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Intangible assets			57
Reblozyl | Operating Segments | Pharmaceutical segment
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Sales			166	17	0
AstraZeneca | Lynparza | Sales-Based Milestones
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Probable contingent payments			600
Liabilities			600
Milestone payments made to collaborative partner			400		550
AstraZeneca | Lynparza | Collaborative Arrangement, Transaction with Party to Collaborative Arrangement
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Potential future sales-based milestone payments			2,100
Regulatory milestone payments accrued			105
Potential future regulatory milestone payments			1,100
AstraZeneca | Lynparza | Regulatory Milestones
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Milestone payments made to collaborative partner			250		160
Eisai
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
License option payment related to collaborative arrangement		$ 125
Eisai | Lenvima | Sales-Based Milestones
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Milestone payments made to collaborative partner			600	200	500
Eisai | Lenvima | Collaborative Arrangement, Transaction with Party to Collaborative Arrangement
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Potential future sales-based milestone payments			2,600
Eisai | Lenvima | Regulatory Milestones
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Milestone payments made to collaborative partner			50	$ 75	10
Bayer AG | Adempas | Sales-Based Milestones
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Milestone payments made to collaborative partner			$ 400		$ 375
Bristol Myers Squibb | Licensing Agreements
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Royalty rate, percentage	22.00%
Royalty rate, deduction, percentage	50.00%		50.00%
Royalties			$ 146
Bristol Myers Squibb | Licensing Agreements | Minimum
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Royalty rate, percentage	20.00%		20.00%
Bristol Myers Squibb | Licensing Agreements | Maximum
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Royalty rate, percentage	24.00%		24.00%
Bristol Myers Squibb | Licensing Agreements | Regulatory Milestones
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Contingent payments collaborative arrangement			$ 20
Bristol Myers Squibb | Licensing Agreements | Sales-Based Milestones
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Contingent payments collaborative arrangement			$ 80